Topic

Zanzalintinib (XL092) [investigational]

A collection of 30 issues

Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in Michigan: Clinical Trials, Compassionate Use, and Appeals Guide 2025

Answer Box: Your Path to Zanzalintinib Access Zanzalintinib (XL092) is an investigational drug not yet FDA-approved. UnitedHealthcare typically denies coverage outside clinical trials. Your fastest path: 1) Search active trials at ClinicalTrials.gov for "XL092" or contact your oncologist about STELLAR program studies, 2) If trial-ineligible, pursue Exelixis
7 min read

Work With Your Doctor to Get Zanzalintinib (XL092) Approved by UnitedHealthcare in Virginia: Clinical Evidence, Appeals, and Expanded Access

Answer Box: Getting Started Zanzalintinib (XL092) is investigational and typically requires expanded access through Exelixis rather than insurance coverage. However, if your oncologist believes insurance coverage for routine care costs is appropriate, here's your fastest path: 1. Visit prep: Gather your complete treatment history, molecular testing results, and
7 min read

Getting Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Appeals Guide with Forms and External Review

Answer Box: Getting Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Pennsylvania Zanzalintinib (XL092) is an investigational multi-target TKI from Exelixis with no FDA approval, making Blue Cross Blue Shield coverage challenging but not impossible. Fastest path: Submit a medical necessity appeal through your Blue Cross Blue Shield plan&
7 min read

How to Get Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Virginia: Clinical Trial Access and Compassionate Use Guide

Answer Box: Getting Zanzalintinib (XL092) Coverage in Virginia Zanzalintinib (XL092) is not FDA-approved and typically isn't covered by Blue Cross Blue Shield Virginia outside clinical trials. Your fastest path: 1) Check ClinicalTrials.gov for ongoing STELLAR program studies, 2) Contact Exelixis directly about compassionate use programs, and 3)
5 min read